Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Neoplasms

Symptoms and General Pathology

Gland and Hormone Related Diseases

Rare Diseases

Kidney Diseases

Neoplasm Metastasis

Hyperparathyroidism

Hyperparathyroidism, Secondary

Neoplastic Processes

Parathyroid Diseases

Endocrine System Diseases

Chronic Graft Versus Host Disease

All Drugs and Chemicals

Bone Density Conservation Agents

Micronutrients

Vitamins

Cinacalcet

Vitamin D

Cholecalciferol

1 alpha-hydroxyergocalciferol

Trace Elements

Hormones

Calcium

Calcium, Dietary

Hormone Antagonists

Vitamin D3

Calciferol

Sensipar®

The purpose of this study is to compare the proportion of chronic kidney disease (CKD) subjects on dialysis receiving Sensipar® and low dose vitamin D or escalating doses of vitamin D alone who are able to achieve the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) secondary hyperparathyroidism (HPT) treatment targets for both biointact parathyroid hormone (biPTH) and calcium-phosphorus (Ca x P) product.

ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism

ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism: A Comparison of Sensipar® and Low Dose Vitamin D vs. Escalating Doses of Vitamin D Alone

Proportion of subjects in each treatment group simultaneously achieving the National Kidney Foundation - Kidney Disease Outcome Quality Initiative (NKF-K/DOQI) targets for both biPTH (80-160 pg/mL, equivalent to iPTH 150-300 pg/mL) and Ca x P (\< 55 mg\^2/dL\^2) during the assessment phase (last 11 weeks of study following a 16-week titration phase)

Absolute change from baseline for serum phosphorus (P) during the assessment phase

Proportion of participants with ≥ 30% reduction from baseline in mean intact parathyroid hormone (iPTH) during the assessment phase.

Percent Change from Baseline for Calcium (Ca) During the Assessment Phase

Percent change from baseline for Phosphorus (P) during the assessment phase

Percent change from baseline for calcium x phosphorus (Ca x P) during the assessment phase

Percent change from baseline for intact parathyroid hormone (iPTH) during the assessment phase

Proportion of participants who attained the K/DOQI target range for calcium x phosphorus (Ca x P) during the assessment phase.

Proportion of participants who attained the K/DOQI target range for calcium (Ca) during the assessment phase.

Proportion of participants who attained the K/DOQI target range for intact parathyroid hormone (iPTH) during the assessment phase.

Proportion of participants who attained the K/DOQI target range for phosphorus (P) during the assessment phase.

Absolute change from baseline for intact parathyroid hormone (iPTH) during the assessment phase.

Absolute change from baseline for calcium (Ca) during the assessment phase

Absolute change from baseline for calcium x phosphorus (Ca x P) during the assessment phase.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism	NCT00135304	Secondary Hyper...	Sensipar® Vitamin D	18 Years -	Amgen
ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism	NCT00135304	Secondary Hyper...	Sensipar® Vitamin D	18 Years -	Amgen

Spots Global Cancer Trial Database for sensipar®

Every month we try and update this database with for sensipar® cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for sensipar®

Every month we try and update this database with for sensipar® cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for sensipar® cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.